



Express Mail No.: EV452774832US

**THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Zeldis

Confirmation No.: 1866

Application No.: 10/699,110

Group Art Unit: 1614

Filed: October 30, 2003

Examiner: To Be Assigned

For: METHODS OF USING AND  
COMPOSITIONS COMPRISING  
SELECTIVE CYTOKINE  
INHIBITORY DRUGS FOR  
TREATMENT AND  
MANAGEMENT OF MACULAR  
DEGENERATION

Attorney Docket No.: 9516-083-999

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to references **A82** to **A86** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant."

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing reference and that the reference be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), Applicants estimate that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: March 25, 2005

by Yeahsil Moon Reg. No. 52,042 35,203  
Anthony M. Insogna (Reg. No.)

JONES DAY  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6702  
(212) 326-3939

Enclosures

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.

9516-083-999

APPLICATION NO.

10/699,110

APPLICANT

Zeldis

FILING DATE

October 30, 2003

GROUP

1614

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A82	5,770,589	6/23/98	Billson et al.			
	A83	5,605,914	2/25/97	Muller			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

A84	Bressler, 1999, "Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP Report 1," Archives of Ophthalmol. 117(10):1329-1345
A85	Hunt, 2002, Rostaporfin (Miravant Medical Technologies) IDrugs 5(2):180-186
A86	Ohno-Matsui et al., 2001, "Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors FEGF and PEDF," J. Cell. Physiol. 189(3):323-333

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.